THE ECONOMIC IMPLICATIONS OF RASBURICASE TREATMENT IN ADULT TUMOR LYSIS SYNDROME PATIENTS

被引：0
|
作者：
Eaddy, M. [1 ]
Seal, B. [2 ]
Tangirala, M. [3 ]
O'Day, K. [1 ]
机构：
[1] Xcenda, Palm Harbor, FL USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Smith Harley Consulting Grp LLC, Lake Mary, FL USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73261-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A40 / A40
页数：1
相关论文
共 50 条
  • [41] Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma
    Personett, Heather A.
    Barreto, Erin F.
    McCullough, Kristen B.
    Dierkhising, Ross
    Leung, Nelson
    Habermann, Thomas M.
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2271 - 2277
  • [42] SINGLE DOSE/SINGLE VIAL RASBURICASE IN THE MANAGEMENT OF PAEDIATRIC PATIENTS WITH HYPERUICEMIA/TUMOR LYSIS SYNDROME
    Dwivedi, Pankaj
    Bhosale, Bharat
    Chinnaswamy, Girish
    Arora, Brijesh
    Banavali, S. D.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S84 - S84
  • [43] Recombinant urate oxidase (Rasburicase): A new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome
    Cairo, MS
    CLINICAL LYMPHOMA, 2003, 3 (04): : 233 - 234
  • [44] Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
    Pession, Andrea
    Melchionda, Fraia
    Castellini, Claudia
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 129 - 141
  • [45] Revised Indication for Hemodiafiltration during the Treatment of Tumor Lysis Syndrome Associated with Pediatric Oncology in the Era of Rasburicase
    Iwahashi, Madoka
    Kobayashi, Kenichiro
    Hamabata, Takayuki
    Kawachi, Sinpei
    Yamagami, Yuji
    Suga, Takenori
    Maihara, Toshiro
    Usami, Ikuya
    Heike, Toshio
    PEDIATRIC BLOOD & CANCER, 2020, 67
  • [46] Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome
    Patel, Samit
    Le, Ann
    Gascon, Sunshine
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (12) : 1015 - 1016
  • [47] Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase
    Hummel, Margit
    Reiter, Sebastian
    Adam, Katja
    Hehlmann, Ruediger
    Buchheidt, Dieter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (04) : 331 - 336
  • [48] Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? In reply
    Coiffier, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3431 - 3432
  • [49] Current information on the treatment of tumoral lysis syndrome -: Place of rasburicase (Fasturtec®)
    Urbieta, M
    ARCHIVES DE PEDIATRIE, 2005, 12 : 8 - 12
  • [50] Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome
    Jeon, Young-Woo
    Kwak, Dae-Hun
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Min, Chang-Ki
    Lee, Jong-Wook
    Min, Woo-Sung
    Cho, Seok-Goo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (09): : 595 - 603
12345